Payment overview · 2025
General Payments
$1,482.47
26 reported records · 8 companies
Healthcare provider profile · identity verified
Arman Ossia, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BURBANK, CA · NPI 1811151681
Verified facts
What the public records show
CMS Open Payments records show Arman Ossia, M.D. received $1,482.47 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $377.75 | 25.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $323.35 | 21.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $267.66 | 18.1% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $167.06 | 11.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.58 | 11.2% | 6 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $126.00 | 8.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.89 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.18 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,482.47 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $377.75 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $323.35 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $267.66 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $167.06 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.72 | 5 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $126.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.65 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 180 | 39 |
| Omeprazole | Omeprazole | 171 | 33 |
| Losartan Potassium | Losartan Potassium | 164 | 34 |
| Metformin Hcl | Metformin Hcl | 136 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 21 |
| Lisinopril | Lisinopril | 80 | 13 |
| Meloxicam | Meloxicam | 77 | 15 |
| Furosemide | Furosemide | 76 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 26 |
| Gabapentin | Gabapentin | 62 | 13 |
| Azithromycin | Azithromycin | 61 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 60 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 23 |
| Potassium Chloride | Potassium Chloride | 60 | suppressed |
| Lovastatin | Lovastatin | 57 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | suppressed |
| Hydrocortisone | Hydrocortisone | 53 | 16 |
| Propranolol Hcl | Propranolol Hcl | 51 | 15 |
| Simvastatin | Simvastatin | 46 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,482.47 · 26 records | ABBVIE INC. | Da Vinci Surgical System, EVENITY, FARXIGA, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, XIFAXAN, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error